Genetic analysis can reduce adverse drug reactions by 30 per cent
Patients can experience 30 per cent fewer serious adverse reactions if their drugs are tailored to their genes, reports a study published in The Lancet. A European collaboration involving researchers from Karolinska Institutet suggests that a genetic analysis prior to drug therapy could significantly reduce suffering and healthcare costs.
Antibody candidate for treating serious liver disease
A study led by researchers from Karolinska Institutet has identified a drug candidate for the treatment of non-alcoholic fatty liver disease, a condition that affects many people with type 2 diabetes. The preclinical study, published in the Journal of Hepatology, indicates that an antibody that blocks the protein VEGF-B presents a possible therapeutic option.
From Ukraine to KI
After fleeing Ukraine – Dariia continues to pursue her medical dreams
Dariia Chernovska was following her dream, studying medicine at Bogomolets National Medical University in Kyiv, when Russia invaded Ukraine and she was forced to flee. Now she is doing an internship at a medical lab and has her sights set on studying medicine at Karolinska Institutet in the fall.
Grants and donations
Two KI researchers awarded ERC Consolidator Grants
Two KI researchers – Simon Elsässer and Magda Bienko – have been awarded 2022 European Research Council (ERC) Consolidator Grants totaling four million euro (nearly 45 million Swedish kronor). The funds will support two ambitious basic research projects that aim to further our understanding of the complex nature of our cells.
Spotlight on proteins
The proteins that fix (almost) everything
Proteins can make any inventor green with envy. It is proteins that make the body work. But when these same super-substances make mistakes, we may get sick with things like cancer or Alzheimer's disease. The job of researchers is to sort out the proteins when they malfunction. Read a special series about protein research from KI's magazine Medicinsk Vetenskap.
Antibodies in the airways provide durable protection against SARS-CoV-2
High levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months. A new study published in The Lancet Infectious Diseases by researchers at Karolinska Institutet and Danderyd Hospital raises further hope for the feasibility of future nasal vaccine platforms.
Selected top publications
Reduced risk of alcohol related disorders in elite football players
Peter Ueda et al, BMJ, December 2022
Vaccination effective and safe in mice with hereditary small vessel disease
Daniel V Oliveira et al, EMBO Molecular Medicine, December 2022
Simultaneous mapping of different epigenetic landmarks in a single cell
Marek Bartosovic and Gonçalo Castelo-Branco, Nature Biotechnology, December 2022
Double embryo transfer during IVF increased risk of complications in singleton births
Kenny A. Rodriguez-Wallberg et al, JAMA Psychiatry, December 2022
Lung function development more plastic than previously thought
Gang Wang et al, American Journal of Respiratory and Critical Care Medicine, November 2022
Study shows how the brain encodes the start, duration and speed of locomotion
Eva M. Berg et al, Neuron, November 2022
Cholinesterase inhibitors helped Alzheimer’s patients preserve kidney function
Hong Xu et al, Kidney International, November 2022
More high impact publications
Scientific challenge to measure inequity in health
How is health equity even calculated? Researchers Emelie Agardh and Matteo Bottai at Karolinska Institutet are looking for new methodological paths, among other things inspired by the game Master mind.